TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19816648
Drug: Weekly risedronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly risedronate
Study: 11575038
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received conventional therapy (antidepressant paroxetine plus weekly psychotherapy for 8 weeks)
Study: 5309529
Drug: Intradermal jet
Normalized name: Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal jet injection using diluted smallpox vaccine with a titre of 10(6.3) TCID(50)/ml
Study: 5309529
Drug: Intradermal jet
Normalized name: Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal jet injection using diluted smallpox vaccine with a titre of 10(7.0) TCID(50)/ml
Study: 5309529
Drug: Multiple-pressure vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-pressure vaccination using undiluted vaccine
Study: 5309529
Drug: Intradermal jet
Normalized name: Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal jet injection using diluted smallpox vaccine with a titre of 10(6.0) TCID(50)/ml
Study: 5309529
Drug: Intradermal jet
Normalized name: Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal jet injection using diluted smallpox vaccine with a titre of 10(5.0) TCID(50)/ml
Study: 31292007
Drug: Intracavitary steroids
Normalized name: carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracavitary steroids (80 mg of methylprednisolone)
Study: 21811797
Drug: tramadol/APAP (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: tramadol/APAP (37.5 mg/325 mg)
Study: 21811797
Drug: tramadol/APAP and
Approvals — FDA: no, EMA: no, PMDA: no
Description: tramadol/APAP and NSAID combination therapy
Study: 17314577
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg M6G
Study: 11453311
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg moxifloxacin once daily for 10 days
Study: 11453311
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg moxifloxacin once daily for 10 days
Study: 8092599
Drug: 0 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mL/kg magnesium citrate
Study: 8092599
Drug: 4 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL/kg magnesium citrate
Study: 8092599
Drug: 6 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mL/kg magnesium citrate
Study: 8092599
Drug: 8 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mL/kg magnesium citrate
Study: 21309709
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg/day
Study: 3337929
Drug: Naproxen 1500
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 1500 mg/day
Study: 29150968
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no light administered)
Study: 24127200
Drug: Naproxen submicron
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen submicron particle capsules 200 mg
Study: 24127200
Drug: Naproxen tablets
Normalized name: Naproxen Tablets
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen tablets 250 mg
Study: 24127200
Drug: Naproxen submicron
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen submicron particle capsules 400 mg
Study: 24127200
Drug: Naproxen tablets
Normalized name: Naproxen Tablets
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen tablets 500 mg
Study: 16538941
Drug: Mitigator Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitigator Sting and Bite Treatment
Study: 16538941
Drug: Calamine lotion
Normalized name: CALAMINE LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calamine lotion
Study: 11113407
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of propafenone (450 to 675 mg/day)
Study: 11113407
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of propafenone with low-dose quinidine (150 mg/day)
Study: 11113407
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of propafenone plus quinidine (600 mg/day)
Study: 11113407
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (combination of all treatments)
Study: 9082591
Drug: Intravascular laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravascular laser therapy
Study: 3888169
Drug: promethazine 25
Normalized name: promethazine 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: promethazine 25 mg plus scopolamine 0.4 mg with d-amphetamine 10 mg
Study: 3888169
Drug: scopolamine 1
Normalized name: scopolamine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: scopolamine 1 mg with d-amphetamine 10 mg
Study: 3888169
Drug: scopolamine 0.25
Normalized name: scopolamine 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: scopolamine 0.25 mg
Study: 3888169
Drug: scopolamine 0.5
Normalized name: scopolamine 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: scopolamine 0.5 mg
Study: 3888169
Drug: scopolamine 0.6
Normalized name: scopolamine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: scopolamine 0.6 mg
Study: 3888169
Drug: marezine 50
Normalized name: Marezine 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: marezine 50 mg
Study: 15945400
Drug: meclizine 50
Normalized name: meclizine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: meclizine 50 mg
Study: 15945400
Drug: dimenhydrinate 50
Normalized name: dimenhydrinate 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: dimenhydrinate 50 mg
Study: 3888169
Drug: scopolamine 1
Normalized name: scopolamine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: scopolamine 1 mg with d-amphetamine 5 mg
Study: 3888169
Drug: promethazine 25
Normalized name: promethazine 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: promethazine 25 mg with d-amphetamine 10 mg
Study: 3888169
Drug: scopolamine 1
Normalized name: scopolamine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: scopolamine 1 mg
Study: 3888169
Drug: scopolamine 0.8
Normalized name: scopolamine 0.86 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: scopolamine 0.8 mg
Study: 3888169
Drug: promethazine 25
Normalized name: promethazine 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: promethazine 25 mg oral
Study: 3888169
Drug: promethazine 25
Normalized name: promethazine 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: promethazine 25 mg I.M.
Study: 3888169
Drug: promethazine 25
Normalized name: promethazine 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: promethazine 25 mg with scopolamine 0.4 mg
Study: 3888169
Drug: promethazine 25
Normalized name: promethazine 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: promethazine 25 mg oral plus 25 mg I.M. with d-amphetamine 10 mg
Study: 24943480
Drug: 5-hydroxytryptophan (5-HTP)
Normalized name: 5-hydroxytryptophan (5-HTP) 50 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-hydroxytryptophan (5-HTP) 100 mg
Study: 22768457
Drug: Gonadotropin therapy
Normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin therapy
Study: 20880898
Drug: Combined β
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined β blocker and behavioural migraine management
Study: 20880898
Drug: β blocker
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: β blocker alone
Study: 20880898
Drug: Optimised acute
Normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised acute treatment alone
Study: 20880898
Drug: Optimised acute
Normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised acute treatment plus combined β blocker and behavioural migraine management
Study: 27125273
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (hepatitis B)
Study: 11255809
Drug: Actinomycin D
Normalized name: Actinomycin D
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Actinomycin D (one course administered within one week after evacuation of molar tissues)
Study: 11255809
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (intravenous fluid and analgesic drugs only)
Study: 9825577
Drug: Consolidation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation therapy (after achieving complete remission)
Study: 9825577
Drug: Observation (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (no further therapy after complete remission)
Study: 29510398
Drug: Intravenous Diacetylmorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Diacetylmorphine (DAM)
Study: 23600965
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (physiotherapy + acupuncture)
Study: 22005660
Drug: 4 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 × 15 mL of 0.25% bupivacaine
Study: 2246657
Drug: Cyproheptadine (maximal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproheptadine (maximal dose 24 mg/day)
Study: 2246657
Drug: Cyproheptadine (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproheptadine (administered for a minimum of six months at optimal dose)
Study: 2246657
Drug: Cyproheptadine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproheptadine therapy
Study: 31479159
Drug: PD-1 inhibitor
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitor treatment
Study: 30784638
Drug: Active case
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active case finding strategy (combination of active and passive case finding)
Study: 24754313
Drug: Eprotirome 100
Normalized name: Eprotirome
DrugBank: Eprotirome (DB05035)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprotirome 100 μg day(-1)
Study: 24754313
Drug: Eprotirome 200
Normalized name: Eprotirome
DrugBank: Eprotirome (DB05035)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprotirome 200 μg day(-1)
Study: 21312304
Drug: Testofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testofen (600 mg per day)
Study: 19406557
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (two doses of 200mg iron sucrose)
Study: 19406557
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (three doses of 200mg iron sucrose)
Study: 19406557
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (daily 80 mg ferrous sulphate)
Study: 9549575
Drug: Aspirin 1.2
Normalized name: Aspirin 1.2 GM Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 1.2 g daily in 3 divided doses from 2 days before to 14 days after surgery
Study: 9549575
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight dextran 500 ml, infused intravenously at 50 ml/hour during surgery and on each of the following 2 days
Study: 8056005
Drug: Nifedipine (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (specific dosage not mentioned)
Study: 2494249
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate aqueous nasal spray, 400 micrograms daily
Study: 2494249
Drug: Astemizole, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole, 10 mg daily
Study: 2494249
Drug: Both trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both trial medications (beclomethasone and astemizole)
Study: 29912983
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg fast-release melatonin
Study: 28731485
Drug: Conventional comprehensive
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional comprehensive treatment plus high-volume hemofiltration (CBP group)
Study: 28731485
Drug: Conventional comprehensive
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional comprehensive treatment only (non-CBP group), n = 11
Study: 22171668
Drug: Self-tapping implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-tapping implants placed after bone condensing
Study: 22171668
Drug: Non-self-tapping implants
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-self-tapping implants placed after bone condensing
Study: 22171668
Drug: Self-tapping implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-tapping implants placed after bone drilling
Study: 22171668
Drug: Non-self-tapping implants
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-self-tapping implants placed after bone drilling
Study: 22171668
Drug: Both implant
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both implant types placed after bone condensing
Study: 22171668
Drug: Both implant
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both implant types placed after bone drilling
Study: 20873697
Drug: ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketorolac tromethamine ophthalmic solution
Study: 18566549
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with standardized Japanese cedar extract, administered daily to once a week after six weeks.
Study: 18566549
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered in the same manner as SLIT.
Study: 18566549
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with standardized Japanese cedar extract
Study: 12918150
Drug: Oral Tegafur
Normalized name: tegafur
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Oral Tegafur plus intravesical mitomycin
Study: 6890537
Drug: Intradermal BCG
Normalized name: Tice BCG Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal BCG
Study: 6890537
Drug: Antigen G
Normalized name: Blood group antigen G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antigen G (soluble cytoplasmic components of M. piscium and M. balnei)
Study: 31519504
Drug: Distractive video
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distractive video during local anesthetic administration
Study: 28647677
Drug: Buprenorphine (2–4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (2–4 mg; sublingual)
Study: 28647677
Drug: Placebo (tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (tablets with identical shape, color, consistency, and scent)
Study: 19139383
Drug: Rifalazil 25
Normalized name: Rifalazil
DrugBank: Rifalazil (DB04934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifalazil 25 mg once weekly for 8 weeks
Study: 11755953
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg enoxaparin administered 12 hours before and 12 hours after surgery, then once daily for 7 days
Study: 8457049
Drug: Fentanyl 2
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 2 micrograms/ml with bupivacaine 0.01% and epinephrine 0.5 micrograms/ml
Study: 8457049
Drug: Sufentanil 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0.8 micrograms/ml with bupivacaine 0.01% and epinephrine 0.5 micrograms/ml
Study: 27716690
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg/kg loading dose over 15 min, maintained at 0.3 μg/kg/h)
Study: 24249435
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg/day, 28 days on and 14 days off)
Study: 22447964
Drug: Biomarker-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarker-directed therapy (prednisolone or matching placebo based on blood eosinophil count)
Study: 22447964
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (prednisolone for 2 weeks)
Study: 21083889
Drug: golimumab, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: golimumab, 100 mg plus placebo
Study: 21083889
Drug: golimumab, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: golimumab, 50 mg plus MTX
Study: 21083889
Drug: golimumab, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: golimumab, 100 mg plus MTX
Study: 18771050
Drug: Pegylated interferon-alpha2b
Normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon-alpha2b (1.0 microg/kg/week) plus ribavirin (800-1,200 mg/day) for 48 weeks
Study: 18771050
Drug: Recombinant interferon-alpha2b
Normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon-alpha2b (3 million IU three times/week) plus ribavirin (800-1,200 mg/day) for 48 weeks
Study: 15645383
Drug: Peripheral nerve
Normalized name: Peripheral nerve antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral nerve blocks (PNB) with 20 ml bupivacaine 0.5 % + 60 ml prilocaine 1 %
Study: 15645383
Drug: Epidural anaesthesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural anaesthesia (EA) with 12 ‐ 20 ml bupivacaine 0.5 %
Study: 8620704
Drug: Iodinated glycerol
Normalized name: iodinated glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodinated glycerol (IG) 60 mg qid for 16 weeks
Study: 2013587
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (5000 international units once daily)
Study: 2013587
Drug: Standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin (5000 international units three times a day)
Study: 18573149
Drug: Acid gel,
Normalized name: SALICYLIC ACID GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid gel, semi-gel, low-viscosity gel, liquid
Study: 10793593
Drug: S(+)‐ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)‐ketamine 0.5 mg kg‐1 (group K1)
Study: 10793593
Drug: S(+)‐ketamine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)‐ketamine 1.0 mg kg‐1 (group K2)
Study: 1425626
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of ondansetron
Study: 30016396
Drug: Daily remote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily remote monitoring
Study: 31359526
Drug: Compulsory community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compulsory community treatment
Study: 17391302
Drug: Subantimicrobial dose
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subantimicrobial dose doxycycline (SDD) - 20 mg doxycycline twice daily
Study: 16241013
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid (500 mg) 2 hours before the procedure
Study: 12463579
Drug: Fondaparinux (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux (administered not earlier than 6 hours postoperatively)
Study: 7607964
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation (HF XRT) with chemotherapy, total radiation dose of 59.4 Gy, in 1.10 Gy fractions, twice daily at 6‐8 h intervals.
Study: 7607964
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation (HF XRT) with chemotherapy
Study: 31244293
Drug: Post-operative concurrent
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative concurrent chemoradiation (CCRT)
Study: 28663317
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg prednisolone daily for 10 days
Study: 22052139
Drug: RhG‐CSF administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: RhG‐CSF administered as a subcutaneous single dose of 10 μg/kg
Study: 22052139
Drug: RhG‐CSF administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: RhG‐CSF administered as 10 μg/kg/s.c./day once daily for 3 days
Study: 19536424
Drug: Tramiprosate 100
Normalized name: TRAMIPROSATE
DrugBank: Tramiprosate (DB06527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramiprosate 100 mg BID
Study: 19536424
Drug: Tramiprosate 150
Normalized name: TRAMIPROSATE
DrugBank: Tramiprosate (DB06527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramiprosate 150 mg BID
Study: 10558961
Drug: Combination hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination hepatitis A/hepatitis B vaccine (3 different manufacturing consistency lots)
Study: 10558961
Drug: Combination hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination hepatitis A/hepatitis B vaccine
Study: 10558961
Drug: Separate but
Normalized name: trans-but-2-enedioic acid
DrugBank: Fumaric acid (DB01677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate but concurrent injections of hepatitis A and hepatitis B vaccines
Study: 6338856
Drug: Thioridazine hydrochloride
Normalized name: Thioridazine Hydrochloride
DrugBank: Thioridazine (DB00679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thioridazine hydrochloride (during administration)
Study: 30103529
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and folic acid (IFA) supplements
Study: 30103529
Drug: Medium-quantity lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-quantity lipid-based nutrient supplements (MQ-LNS)
Study: 15242865
Drug: IFN beta
Normalized name: IFN beta2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN beta 2.2 microg (0.05 ml)